Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) SVP C Frank Bennett sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $40.53, for a total value of $202,650.00. Following the transaction, the senior vice president now directly owns 4,627 shares of the company’s stock, valued at approximately $187,532. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on ISIS. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of ISIS Pharmaceuticals in a research note on Thursday. They now have a $70.00 price target on the stock. Separately, analysts at Laidlaw initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating on the stock. Finally, analysts at Laidlow & Co. initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating and a $52.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $44.92.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded up 0.81% on Thursday, hitting $39.90. 3,274,317 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a 52 week low of $22.25 and a 52 week high of $62.66. The stock has a 50-day moving average of $32.82 and a 200-day moving average of $36.49. The company’s market cap is $4.698 billion. ISIS Pharmaceuticals also saw some unusual options trading activity on Thursday. Stock traders purchased 3,097 call options on the company. This represents an increase of approximately 231% compared to the typical daily volume of 937 call options.

ISIS Pharmaceuticals (NASDAQ:ISIS) last announced its earnings results on Monday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Analysts expect that ISIS Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

Receive News & Ratings for ISIS Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ISIS Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.